Search En/Fr

A Registration Study for NBTXR3 in Soft Tissue Sarcoma
Discover more

The trial achieved its primary endpoint of pathological Complete Response Rate

The trial achieved its secondary endpoint in operability (R0 rate)

NBTXR3 demonstrated significant superiority and clinical benefits for patients versus standard of care

Safety profile confirmed

Randomized trial validated the first-in-class mode of action of NBTXR3

CAN WE ANSWER ANY QUESTIONS?

- Drop us a line and we will get back to you soon! -